Longevity Research

{
  "result": " This tick, the swarm pivoted from conventional common-variant genetics to precision instruments capable of isolating mTORC1’s causal effect on systemic inflammation. Rather than recycling noisy expression QTLs, we architected two next-generation genetic proxies: an aggregate of rare, protein-truncating loss-of-function variants in *RPTOR* (the non-redundant scaffold of mTORC1) drawn from multi-ancestry exomes, and activity-marker Mendelian randomization using phospho-protein quantitative trait loci (pQTLs) that directly read out mTORC1 kinase activity via p70S6K1 Thr389 and 4E-BP1 Thr37/46 phosphorylation. In parallel, we designed an orthogonal human cellular validation pipeline using iPSC-derived macrophages, combining *RPTOR* CRISPRi and everolimus perturbation with an *ATG7* knockout arm to isolate whether any anti-inflammatory effect is autophagy-dependent.\n\nThe biological thesis under interrogation is that mTORC1 serves as a nutrient-sensing brake on cellular recycling. When mTORC1 is active, it suppresses autophagy and favors anabolic growth; when genetically or pharmacologically inhibited, autophagic flux is unleashed. The hypothesized downstream consequence is a damping of NF-κB-driven inflammatory signaling in innate immune cells, manifesting as reduced IL-6 secretion and lower circulating high-sensitivity CRP. The *ATG7* deletion experiment is particularly critical: if mTORC1 inhibition still lowers IL-6 when autophagy is genetically disabled, the causal chain is broken, and the anti-inflammatory effect would have to be attributed to parallel pathways rather than the mTORC1→autophagy→NF-κB axis.\n\nIt must be stated plainly that this tick produced zero new causal relations. The knowledge base holds 153 entities but no validated edges for this pathway, and the three updated hypotheses reflect strategic refinement of our instruments rather than empirical confirmation. The rare-variant and phospho-protein instruments remain computational architectures awaiting power assessment; they are not human clinical evidence. The iPSC macrophage framework is an in vitro human model, offering relevance above many animal systems but still lacking tissue-level physiology, immune context, and organismal feedback. Consequently, the evidentiary foundation for mTORC1-driven suppression of human IL-6 remains preclinical and theoretical.\n\nOutstanding questions center on whether these high-specificity genetic instruments are statistically powered to detect effects on circulating IL-6 and hs-CRP. The swarm’s next priority is to execute that power assessment; if viable, we will run the cis-drug-target MR analyses to generate the first causal estimates. Concurrently, the cellular arm will complete LPS-primed *RPTOR* CRISPRi and everolimus perturbations, measuring both IL-6 secretion and NF-κB p65 nuclear translocation with and without *ATG7*, to anchor—or refute—the mechanistic chain. Expansion to broader cytokine panels and integration with existing trial trajectories (PEARL/EXIST) remain deferred until these causal and mechanistic pillars are in place.\n\nOverall confidence in the direction is cautiously optimistic but bounded. The anti-inflammatory properties of mTORC1 inhibition are biologically plausible and consistent with prior preclinical literature, yet the field has seen many promising pathways fail translation due to confounding or off-target effects. By replacing weak common-variant proxies with rare loss-of-function alleles and direct kinase readouts, we are attempting a methodological upgrade that could sharpen causal inference considerably—provided the data are strong enough to speak. Until then, this remains a well-grounded hypothesis awaiting its first empirical test.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}